BackAmbrx Biopharma Overview

Ambrx Biopharma Long Term Debt

Track Ambrx Biopharma's long-term debt ($8.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$8.61M

Peer trimmed avg / median

Loading

Ambrx Biopharma Long Term Debt History

Loading

Ambrx Biopharma vs. peers: Long Term Debt Comparison

Loading

Ambrx Biopharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ambrx Biopharma (AMAM) FAQ

Ambrx Biopharma (AMAM) currently reports a long-term debt of $8.6M as of September 2023. In the prior-year period, the figure was $0. Use the charts on this page to explore Ambrx Biopharma's long-term debt history and peer comparisons.

Ambrx Biopharma's long-term debt changed from $0 to $8.6M (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ambrx Biopharma reported $8.6M in long-term debt as of September 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $8.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ambrx Biopharma, and consider following AMAM for alerts when major investors trade the stock.

Ambrx Biopharma is classified in the Healthcare sector. On long-term debt, it currently shows $8.6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AMAM with unrelated industries.